Drug Target Review explores antiviral Fc-conjugates and how they could be used as a COVID-19 prophylactic and therapeutic with Dr Jeff Stein, Cidara’s President and CEO.
List view / Grid view
Mundipharma launches Remsima®▼ (infliximab), a new-generation value-based monoclonal antibody, in six European markets
25 February 2015 | By Mundipharma
Mundipharma International Limited’s network of independent associated companies are launching Remsima® (infliximab) this month in Germany, Italy, UK, Netherlands, Belgium and Luxembourg following expiry of the relevant patents and Supplementary Protection Certificates, having secured distribution rights from Celltrion Healthcare Hungary Kft for Remsima in these markets...